Antiphospholipid antibody syndrome · 4 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Rivaroxaban monotherapy Variant #05 | — | R 1 032 | 90d | — | — | — | — | — |
Warfarin monotherapy N/A - secondary systemic drug | — | R 285 | — | — | — | — | — | — |
Rituximab monotherapy N/A - secondary systemic drug | — | R 52 | 180d | ~20.3 mo | — | ~4 | ~R 208 PFS proxy · indirect | 20 |
Aspirin and Warfarin Variant #01 | — | R 26 | 28d | — | — | — | — | — |
4 of 4 regimens shown